For late arrivals, cancellations, or rescheduling, please email [email protected] This email will only be answered for same day appointments, for all other inquiries please email us at [email protected]
LMC Manna Research’s Chief Medical officer Dr. Ronnie Aronson shares our latest publication showcasing our collaborative work with the medications lixisenatide and LixiLan (lixisenatide & lantus combination) over the past decade. This publication is a post-hoc...
With one month of 2019 already completed, we are excited to share a 2nd FIT published paper from LMC Manna Research’s very own Scientist Team led by Chief Medical Officer Dr. Ronnie Aronson and Senior Scientist Michael Riddell.This 2nd paper highlights that High...
Sanofi announced on July 28th that the U.S. Food and Drug Administration (FDA) approved AdlyxinTM (lixisenatide), a once-daily mealtime GLP-1 receptor agonist injection indicated as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes. “The...
Toronto, February 1st, 2016 – LMC Diabetes & Endocrinology, the largest private Diabetes clinical research network in North America, announced their collaboration with Dr. Michael Riddell, PhD, a leading researcher in metabolic and hormonal responses to...
